Abexinostat
Abexinostat (INN, formerly PCI-24781) is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. and is in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well. Abexinostat exerts its effect as a pan-histone deacetylase inhibitor and inhibits RAD51, which is involved in repairing DNA double strand breaks. References

Benzofuran-2-carboxamides
Hydroxamic acids
Histone deacetylase inhibitors
Antineoplastic drugs
Experimental cancer drugs
Benzamides
2-Phenoxyethanamines